These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15948275)

  • 41. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir: what have over 1 million years of patient experience taught us?
    Pozniak A
    Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
    Nurutdinova D; Onen NF; Hayes E; Mondy K; Overton ET
    Ann Pharmacother; 2008 Nov; 42(11):1581-5. PubMed ID: 18957630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease.
    Winston JA; Shepp DH
    Clin Infect Dis; 2006 Jun; 42(11):1657-8; author reply 1658. PubMed ID: 16652330
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-HIV agents. Merck integrase inhibitor.
    TreatmentUpdate; 2006; 18(4):3-4. PubMed ID: 17205652
    [No Abstract]   [Full Text] [Related]  

  • 47. HIV/AIDS. At last, vaginal gel scores victory against HIV.
    Cohen J
    Science; 2010 Jul; 329(5990):374-5. PubMed ID: 20643914
    [No Abstract]   [Full Text] [Related]  

  • 48. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
    Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
    Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [HIV-HBV-coinfection--diagnosis and therapy].
    Koch S; Göbels K; Oette M; Heintges T; Erhardt A; Häussinger D
    Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1873-7. PubMed ID: 16915550
    [No Abstract]   [Full Text] [Related]  

  • 50. Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
    Gordien E; Bouhassoune K; Calboreanu A; Alloui C; Rico-Garcia M; Salmon-Céron D; Legal F; Dény P; Sogni P; Podevin P
    Int J STD AIDS; 2006 Sep; 17(9):635-8. PubMed ID: 16942658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug therapy: tenofovir.
    Lok AS
    Hepatology; 2010 Aug; 52(2):743-7. PubMed ID: 20597070
    [No Abstract]   [Full Text] [Related]  

  • 52. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Barreiro P; Soriano V
    J Antimicrob Chemother; 2006 May; 57(5):806-9. PubMed ID: 16531427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
    Psevdos G; Gonzalez E; Sharp V
    AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Further indications for tenofovir].
    Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207
    [No Abstract]   [Full Text] [Related]  

  • 55. An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
    Watanabe T; Tokumoto Y; Hirooka M; Koizumi Y; Tada F; Ochi H; Abe M; Kumagi T; Ikeda Y; Matsuura B; Takada K; Hiasa Y
    Intern Med; 2014; 53(12):1343-6. PubMed ID: 24930654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early end for FEM-PrEP HIV prevention trial.
    AIDS Patient Care STDS; 2011 Jun; 25(6):383. PubMed ID: 21612547
    [No Abstract]   [Full Text] [Related]  

  • 57. Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir.
    Kumar N; Bower M; Nelson M
    Int J STD AIDS; 2012 Jan; 23(1):59-60. PubMed ID: 22362693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience.
    Moore S; Myint MM; Galau NH
    AIDS; 2010 Jun; 24(10):1606-7. PubMed ID: 20539097
    [No Abstract]   [Full Text] [Related]  

  • 59. HIV clinics are halting enrolment of new patients as funding stalls, MSF warns.
    Roehr B
    BMJ; 2009 Jul; 339():b2966. PubMed ID: 19620230
    [No Abstract]   [Full Text] [Related]  

  • 60. [HIV and AIDS: what's new in 2010?].
    Calmy A; Schiffer V; Hirschel B
    Rev Med Suisse; 2011 Jan; 7(278):159-63. PubMed ID: 21400951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.